News

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.
China is being viewed by the biotech and life sciences industry as a threat to US innovation. One pharma CEO thinks it may ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...
CSPC received an upfront payment of $100 million from AstraZeneca and is also eligible to receive up to $1.92 billion for further development and commercialization milestones, plus tiered royalties.
AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in ...
AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...
On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City.
AstraZeneca said it would have access to CSPC's pre-clinical candidate small molecule - YS2302018 - an oral Lp(a) disruptor, with the aim to develop it as a lipid-lowerin.
AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC).As part of the deal, AstraZeneca will pay ...